How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cartilage Diseases Market
- By Disease Type: Osteoarthritis, Rheumatoid Arthritis, Chondromalacia Patella, Relapsing Polychondritis, Traumatic Cartilage Injury
- By Treatment Type: Pharmacological Therapy, Surgical Intervention, Physical Therapy, Regenerative Medicine, Orthobiologics
- By Product Type: Cartilage Repair Devices, Cartilage Regeneration Products, Pain Management Drugs, Anti-inflammatory Drugs, Diagnostic Imaging Systems
- By End User: Hospitals, Orthopedic Clinics, Rehabilitation Centers, Ambulatory Surgical Centers, Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Osteoarthritis leads By Disease Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 18 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Cartilage Diseases Market report
A complete, evidence-based study - 11 chapters and 121 sections covering market size, segmentation across 4 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Disease Type 5
Treatment Type 5
Product Type 5
End User 5
Companies profiled
Zimmer Biomet Holdings Inc.
Stryker Corporation
Smith & Nephew plc
Arthrex Inc.
DePuy Synthes (Johnson & Johnson)
Medtronic plc
Mitek Sports Medicine (a division of Johnson & Johnson)
Conmed Corporation
B. Braun Melsungen AG
Exactech Inc.
LimaCorporate S.p.A.
OsteoMed
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Zimmer Biomet Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Smith & Nephew plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Arthrex Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →DePuy Synthes (Johnson & Johnson)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Mitek Sports Medicine (a division of Johnson & Johnson)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Conmed Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Exactech Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →LimaCorporate S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →OsteoMed
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Tornier
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Inc. (a Wright Medical Group N.V. company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Globus Medical Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →NuVasive
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,469M by 2033 · 4.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Osteoarthritis50.0
- Rheumatoid Arthritis9.9
- Chondromalacia Patella12.2
- Relapsing Polychondritis10.5
- Traumatic Cartilage Injury17.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,246M → $1,930M · 5.6%
Europe$868.5M → $1,301M · 5.2%
Asia Pacific$793.0M → $1,100M · 4.2%
Latin America$490.9M → $698.2M · 4.5%
Middle East and Africa$377.6M → $523.3M · 4.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.702026
4.702027
4.712028
4.732029
4.732030
4.742031
4.762032
4.782033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Zimmer Biomet Holdings Inc.13.8
- Stryker Corporation19.5
- Smith & Nephew plc7.7
- Arthrex Inc.13.9
- DePuy Synthes (Johnson & Johnson)7.3
- Medtronic plc9.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Type22.6%
Treatment Type18.6%
Product Type35.8%
End User23.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.8
- Europe23.4
- Asia Pacific19.8
- Latin America12.6
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings Inc. | 91 | 85 | 80 | 83 | 81 | 77 | 83 |
| Stryker Corporation | 72 | 92 | 87 | 85 | 70 | 87 | 82 |
| Smith & Nephew plc | 85 | 79 | 72 | 70 | 83 | 76 | 78 |
| Arthrex Inc. | 69 | 73 | 77 | 74 | 70 | 64 | 71 |
| DePuy Synthes (Johnson & Johnson) | 75 | 69 | 63 | 60 | 54 | 57 | 63 |
| Medtronic plc | 58 | 52 | 53 | 58 | 52 | 71 | 57 |
| Mitek Sports Medicine (a division of Johnson & Johnson) | 44 | 64 | 46 | 50 | 46 | 50 | 50 |
| Conmed Corporation | 49 | 40 | 40 | 60 | 37 | 59 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Zimmer Biomet Holdings Inc.
- Stryker Corporation
- Smith & Nephew plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Stryker Corporation | ◐ | ◐ | ✓ | ✓ | − | ✓ |
| Smith & Nephew plc | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Arthrex Inc. | ◐ | − | ✓ | ✓ | ◐ | ◐ |
| DePuy Synthes (Johnson & Johnson) | ◐ | ◐ | − | ✓ | − | − |
| Medtronic plc | − | − | ◐ | ◐ | ◐ | ◐ |
| Mitek Sports Medicine (a division of Johnson & Johnson) | ◐ | − | ◐ | − | − | − |
| Conmed Corporation | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Zimmer Biomet Holdings Inc.83
2Stryker Corporation82
3Smith & Nephew plc78
4Arthrex Inc.71
5DePuy Synthes (Johnson & Johnson)63
6Medtronic plc57
7Mitek Sports Medicine (a division of Johnson & Johnson)50
8Conmed Corporation48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Zimmer Biomet Holdings Inc.Stryker CorporationSmith & Nephew plc
Challenger1
Strong scale, closing on the leaders.
Arthrex Inc.
Contender2
Focused players with pockets of strength.
DePuy Synthes (Johnson & Johnson)Medtronic plc
Niche2
Specialists in a single segment or region.
Mitek Sports Medicine (a division of Johnson & Johnson)Conmed Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Type in North America, then scale across Cartilage Diseases Market — a $431M beachhead inside a $7.08B market.
Beachhead (SOM)$431Mobtainable near-term
Serviceable (SAM)$2.68Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Osteoarthritis
Best fit — highest urgency & budget in Disease Type.
Economic buyer79 fit
Rheumatoid Arthritis
Strong fit — clear ROI and a fast path to value.
End user67 fit
Chondromalacia Patella
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Product Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel26%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Disease Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cartilage Diseases Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified23%
Evaluation12%
Closed-won5%
$8.5KCAC
$29KLTV
3.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cartilage Diseases Market is a high-growth opportunity — $1.03B by 2033, compounding at 11.1%.
TAM · 2025$443Mtoday
TAM · 2033$1.03Bforecast
CAGR11.1%2027–2033
Cumulative$6.30Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.03BTotal addressable market
SAM$401MServiceable available market
SOM$88MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.1% CAGR
Demand compounds through 2033, outpacing GDP across Disease Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.03BLarge & growingTAM by 2033 at 11.1% CAGR
$401MServiceable nowreachable with today’s model
$88MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$803MBear7.2% CAGR
$1.03BBase11.1% CAGR
$1.32BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cartilage Diseases Market — a $11.1B market by 2033. Plan: grow share from 8.0% to 15.1%.
Market size · 2033$11.1Btotal addressable
Market CAGR10.5%2027–2033
Target share15.1%from 8.0% today
Revenue ambition$1.67Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 15.1% | At risk |
| Revenue | $953M | $1.67B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.8% | 42.1% | On track |
| Customer retention | 84.3% | 94.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $224M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disease Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cartilage Diseases Market conversation — a $5.57B market you can size, segment and defend in minutes.
Market size · 2033$5.57Btotal opportunity
Growth7.3%CAGR to 2033
Addressable buyers1,153+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Type
Goal Grow share in Disease Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 3 mopayback period
$83K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Zimmer Biomet Holdings Inc.Stryker CorporationSmith & Nephew plcArthrex Inc.DePuy Synthes (Johnson & Johnson)Medtronic plcMitek Sports Medicine (a division of Johnson & Johnson)Conmed Corporation+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cartilage Diseases Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cartilage Diseases Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cartilage Repair and Regeneration Market
Market size, share, segmentation and regional forecast.
$820M market · 2025 base year
View reportCartilage Repair，Cartilage Regeneratio Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCarton Die Cutting And Creasing Machine Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCarton Liners Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCarton Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCarton Moisture Agent Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCarton Packaging Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCarton Packs Maple Water Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCarton Sealer Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportCarton Sealing Tape Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCarton Tray Forming Machine Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCartoon & Animal Helium Foil Mylar Balloons Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.